Dr. Janni on Challenges Facing the Treatment of HER2-Positive Breast Cancer

Wolfgang Janni, MD, PhD
Published: Monday, Apr 17, 2017



Wolfgang Janni, MD, PhD, University of Ulm, discusses challenges facing the treatment options for patients HER2-positive breast cancer.

One of the challenges facing patients with HER2-positive breast cancer is determining the right treatment options for each specific patient. There is a strong standard therapy for metastatic breast cancer in the first-line setting, however, further investigation is also needed in later lines of treatment, explains Janni.

In the adjuvant setting, it is unsure what the right treatment will be and which patients will experience the best response, states Janni.
 


Wolfgang Janni, MD, PhD, University of Ulm, discusses challenges facing the treatment options for patients HER2-positive breast cancer.

One of the challenges facing patients with HER2-positive breast cancer is determining the right treatment options for each specific patient. There is a strong standard therapy for metastatic breast cancer in the first-line setting, however, further investigation is also needed in later lines of treatment, explains Janni.

In the adjuvant setting, it is unsure what the right treatment will be and which patients will experience the best response, states Janni.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x